Results 121 to 130 of about 2,887 (179)

Efficacy and safety of olmesartan medoxomil‑amlodipine besylate tablets (Sevikar^®) in older patients with essential hypertension: Subgroup analysis from the Sevikar study. [PDF]

Exp Ther Med
Cui Z, Qiu Z, Cheng W, Hu W, Ma G, Cai X, Jin Y, Zhao Y, He L, Li Y, Bu P, Chen X, Wang R, Chen L, Dong P, Feng L, Han X, Hong M, Hou Y, Liao M, Wang M, Wang X, Xie J, Xu Y, Wang Z, Huang K, Li Y, Li D, Ji X, Huang J, Wang J, Fang D, Wang J, Tang L, Liu Y, Fu G, Du J, Wang L, Liu M, Ge J.   +39 more
europepmc   +1 more source

Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. [PDF]

Int J Nanomedicine, 2019
Albash R, El-Nabarawi MA, Refai H, Abdelbary AA.   +3 more
europepmc   +1 more source

Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single-arm, multi-center, real-world study. [PDF]

J Clin Hypertens (Greenwich)
Cui Z, Qiu Z, Cheng W, Hu W, Ma G, Cai X, Jin Y, Zhao Y, He L, Li Y, Bu P, Chen X, Wang R, Chen L, Dong P, Feng L, Han X, Hong M, Hou Y, Liao M, Wang M, Wang X, Xie J, Xu Y, Wang Z, Huang K, Li Y, Li D, Ji X, Huang J, Wang J, Fang D, Wang J, Tang L, Liu Y, Fu G, Du J, Wang L, Liu M, Ge J.   +39 more
europepmc   +1 more source

Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients. [PDF]

J Clin Hypertens (Greenwich), 2018
Redon J, Weber MA, Reimitz PE, Wang JG.
europepmc   +1 more source

Small bowel enteropathy associated with olmesartan medoxomil treatment. [PDF]

Ann Gastroenterol, 2017
Galanopoulos M, Varytimiadis L, Tsigaridas A, Karatzas PS, Archavlis E, Viazis N, Vourlakou C, Mantzaris GJ.   +7 more
europepmc   +1 more source

Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. [PDF]

J Clin Hypertens (Greenwich), 2018
Bakris GL, Zhao L, Kupfer S, Juhasz A, Hisada M, Lloyd E, Oparil S.   +6 more
europepmc   +1 more source

Linear mixed-effects model of QTc prolongation for olmesartan medoxomil. [PDF]

J Clin Pharmacol, 2016
Song S, Matsushima N, Lee J, Mendell J.
europepmc   +1 more source

Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. [PDF]

J Clin Hypertens (Greenwich), 2017
Neutel JM, Cushman WC, Lloyd E, Barger B, Handley A.   +4 more
europepmc   +1 more source